Company Analysis: Regeneron

Company Analysis: Regeneron

  • January 2021 •
  • 53 pages •
  • Report ID: 6102714 •
  • Format: PDF
PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Regeneron’s prescription pharmaceutical business has solid near-term growth but will see a long-term decline due to Eylea biosimilars.
Key themes – [1] Eylea sales will peak in 2022 as biosimilar competition begins in the US in 2023 [2] Collaboration revenue will continue to grow, driven by Dupixent and international Eylea sales.

Model updates (6 November 2020)

Eylea forecast adjusted higher due to strong rebound in sales
REGN-COV2 added to forecast.

Model updates (5 August 2020)

Eylea forecast adjusted lower due to COVID-19 impact
Libtayo forecast adjusted lower due to sales trends.

Model updates (5 May 2020)

Praluent forecast added due to restructuring of Sanofi agreement
Libtayo forecast adjusted higher due to recent trial data from non-small cell lung cancer and basal cell carcinoma.

Model updates (6 February 2020)

Eylea forecast adjusted higher due to continued share gains.